Literature DB >> 24861880

Editorial commentary on "Analysis of IDH mutation, 1p19q deletion, and PTEN loss delineates prognosis in clinical low-grade gliomas".

Robert B Jenkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24861880      PMCID： PMC4057144          DOI： 10.1093/neuonc/nou100

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  13 in total

1.  The somatic genomic landscape of glioblastoma.

Authors:  Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

2.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

Authors:  Patrick J Killela; Zachary J Reitman; Yuchen Jiao; Chetan Bettegowda; Nishant Agrawal; Luis A Diaz; Allan H Friedman; Henry Friedman; Gary L Gallia; Beppino C Giovanella; Arthur P Grollman; Tong-Chuan He; Yiping He; Ralph H Hruban; George I Jallo; Nils Mandahl; Alan K Meeker; Fredrik Mertens; George J Netto; B Ahmed Rasheed; Gregory J Riggins; Thomas A Rosenquist; Mark Schiffman; Ie-Ming Shih; Dan Theodorescu; Michael S Torbenson; Victor E Velculescu; Tian-Li Wang; Nicolas Wentzensen; Laura D Wood; Ming Zhang; Roger E McLendon; Darell D Bigner; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Hai Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

3.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

4.  Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.

Authors:  Nesrin Sabha; Christiane B Knobbe; Majula Maganti; Soha Al Omar; Mark Bernstein; Rob Cairns; Besmira Çako; Andreas von Deimling; David Capper; Tak W Mak; Tim-Rasmus Kiehl; Philippe Carvalho; Evelyn Garrett; Arie Perry; Gelareh Zadeh; Abhijit Guha
Journal:  Neuro Oncol       Date:  2014-07       Impact factor: 12.300

5.  IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.

Authors:  Daniel Gorovets; Kasthuri Kannan; Ronglai Shen; Edward R Kastenhuber; Nasrin Islamdoust; Carl Campos; Elena Pentsova; Adriana Heguy; Suresh C Jhanwar; Ingo K Mellinghoff; Timothy A Chan; Jason T Huse
Journal:  Clin Cancer Res       Date:  2012-03-13       Impact factor: 13.801

6.  IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

Authors:  Martin J van den Bent; Hendrikus J Dubbink; Yannick Marie; Alba A Brandes; Martin J B Taphoorn; Pieter Wesseling; Marc Frenay; Cees C Tijssen; Denis Lacombe; Ahmed Idbaih; Ronald van Marion; Johan M Kros; Winand N M Dinjens; Thierry Gorlia; Marc Sanson
Journal:  Clin Cancer Res       Date:  2010-02-16       Impact factor: 13.801

7.  IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

Authors:  C Houillier; X Wang; G Kaloshi; K Mokhtari; R Guillevin; J Laffaire; S Paris; B Boisselier; A Idbaih; F Laigle-Donadey; K Hoang-Xuan; M Sanson; J-Y Delattre
Journal:  Neurology       Date:  2010-10-26       Impact factor: 11.800

8.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079

9.  A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation.

Authors:  Robert B Jenkins; Yuanyuan Xiao; Hugues Sicotte; Paul A Decker; Thomas M Kollmeyer; Helen M Hansen; Matthew L Kosel; Shichun Zheng; Kyle M Walsh; Terri Rice; Paige Bracci; Lucie S McCoy; Ivan Smirnov; Joseph S Patoka; George Hsuang; Joe L Wiemels; Tarik Tihan; Alexander R Pico; Michael D Prados; Susan M Chang; Mitchel S Berger; Alissa A Caron; Stephanie R Fink; Chandralekha Halder; Amanda L Rynearson; Brooke L Fridley; Jan C Buckner; Brian P O'Neill; Caterina Giannini; Daniel H Lachance; John K Wiencke; Jeanette E Eckel-Passow; Margaret R Wrensch
Journal:  Nat Genet       Date:  2012-08-26       Impact factor: 41.307

10.  Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.

Authors:  Kasthuri Kannan; Akiko Inagaki; Joachim Silber; Daniel Gorovets; Jianan Zhang; Edward R Kastenhuber; Adriana Heguy; John H Petrini; Timothy A Chan; Jason T Huse
Journal:  Oncotarget       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.